The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Background Final data are presented for the ORAL Sequel long-term extension (LTE) study
evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 …

Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …

Objectives To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid
arthritis patients receiving JAK inhibitors. Methods We conducted a systematic literature …

The Janus kinase (JAK)–signal transducer of activators of transcription (STAT) pathway is
now recognized as an evolutionarily conserved signaling pathway employed by diverse …

Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers
and Activators of Transcription) pathway, play a central role in the pathogenesis of …

Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine …

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterised by
infiltration of immune cells into the affected synovium, release of inflammatory cytokines and …

Objective JAK inhibitor therapies are effective treatment options for immune‐mediated
inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism …